Literature DB >> 2094690

Assessment of variables contributing to cyclosporine distribution in blood.

S O Broin1, E Clarke, S McCann.   

Abstract

Factors which can account for the poor correlation between whole blood and plasma Cyclosporine (CsA) levels in patients on CsA prophylaxis are evaluated. The study took account of the influence of plasma separation procedures, and the sample haematocrit on CsA distribution in the blood of renal transplant patients (n = 35). CsA was measured using both specific and non-specific CsA radioimmunoassays. Significant negative correlations occurred between CsA distribution and the haematocrit, independently of the plasma separation procedure or the specificity of the assay. All results were lower when using the specific assay but a significantly higher percentage of CsA was measured in the plasma by specific assay compared to nonspecific assay when plasma was separated at both 22 degrees C (t-test, p less than 0.02) and at 37 degrees C, p less than 0.01). This may relate to the selective binding of CsA and its analogues by blood cells. This study is a prelude to the development of more consistent plasma separation procedures in the monitoring of this drug.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2094690     DOI: 10.1007/bf02993609

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  14 in total

1.  Specific 3H radioimmunoassay with a monoclonal antibody for monitoring cyclosporine in blood.

Authors:  P E Ball; H Munzer; H P Keller; E Abisch; J Rosenthaler
Journal:  Clin Chem       Date:  1988-02       Impact factor: 8.327

2.  Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood.

Authors:  M Lemaire; J P Tillement
Journal:  J Pharm Pharmacol       Date:  1982-11       Impact factor: 3.765

3.  Monoclonal antibodies for radioimmunoassay of cyclosporine: a multicenter comparison of their performance with the Sandoz polyclonal radioimmunoassay kit.

Authors:  D W Holt; A Johnston; J T Marsden; L Vernillet; P A Keown; T G Rosano; L M Shaw; J Rosenthaler
Journal:  Clin Chem       Date:  1988-06       Impact factor: 8.327

4.  Monitoring of cyclosporin by monoclonal radioimmunoassay in cardiac transplantation.

Authors:  J C Loo; N Jordan; I J McGilveray; S L Jindal
Journal:  Lancet       Date:  1988-07-16       Impact factor: 79.321

5.  Cyclosporin concentrations in whole blood and plasma.

Authors:  M J Bennett; K H Carpenter; E Worthy; J S Lilleyman
Journal:  Clin Chem       Date:  1984-05       Impact factor: 8.327

6.  In vitro stability of cyclosporin A.

Authors:  J M Hows; J M Smith
Journal:  J Clin Pathol       Date:  1983-06       Impact factor: 3.411

7.  Effects of sample preparation on concentrations of cyclosporin A measured in plasma.

Authors:  R W Yatscoff; D N Rush; J R Jeffery
Journal:  Clin Chem       Date:  1984-11       Impact factor: 8.327

8.  A radioimmunoassay to measure cyclosporin A in plasma and serum samples.

Authors:  P Donatsch; E Abisch; M Homberger; R Traber; M Trapp; R Voges
Journal:  J Immunoassay       Date:  1981

9.  Effect of hematocrit on cyclosporine (cyclosporin A) in whole blood and plasma of renal-transplant patients.

Authors:  T G Rosano
Journal:  Clin Chem       Date:  1985-03       Impact factor: 8.327

10.  Assessment of cyclosporin A in whole blood and plasma in five patients with different hematocrits.

Authors:  R P Agarwal; R A McPherson; G A Threatte
Journal:  Ther Drug Monit       Date:  1985       Impact factor: 3.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.